Advancing Treatment for Pediatric Brain Cancer

ReSPECT-PBC Clinical Trial: Advancing Treatment for Pediatric Brain Cancer Pediatric brain tumors are among the leading causes of cancer-related deaths in children, with limited treatment options for aggressive tumors like ependymoma and high-grade glioma (HGG). The...

Introducing REYOBIQ™

Introducing REYOBIQ™: The FDA-Accepted Proprietary Name for Plus Therapeutics’ Lead Drug Candidate Big News from Plus Therapeutics! The U.S. Food and Drug Administration (FDA) has conditionally accepted the proprietary name REYOBIQ™ (rhenium Re186 obisbemeda) for our...

Advancing Treatment for Leptomeningeal Metastases

Advancing Treatment for Leptomeningeal Metastases (LM): ReSPECT-LM Clinical Trial Now Enrolling Leptomeningeal metastases (LM) is a devastating complication of cancer, occurring when malignant cells spread to the cerebrospinal fluid (CSF) and leptomeninges, leading to...

Nature Publication

Phase 1 Clinical Trial Results for Rhenium (186Re) Obisbemeda in Recurrent Glioblastoma (GBM) Now in Nature Communications 📢 Exciting News! The results of our Phase 1 clinical trial for Rhenium (186Re) Obisbemeda in recurrent glioblastoma (GBM) have been published in...